Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

A Phase 1 Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.

Sullivan RJ, Hollebecque A, Flaherty KT, Shapiro GI, Rodon Ahnert J, Millward MJ, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade AE, Crowe KJ, Flynn DL, Kaufman MD, Henry JR, Peng SB, Benhadji KA, Conti I, Gordon MS, Tiu RV, Hong DS.

Mol Cancer Ther. 2019 Oct 23. pii: molcanther.0681.2019. doi: 10.1158/1535-7163.MCT-19-0681. [Epub ahead of print]

PMID:
31645440
2.

Aurora A selective inhibitor LY3295668 leads to dominant mitotic arrest, apoptosis in cancer cells and shows potent preclinical antitumor efficacy.

Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM.

Mol Cancer Ther. 2019 Sep 17. pii: molcanther.0529.2018. doi: 10.1158/1535-7163.MCT-18-0529. [Epub ahead of print]

PMID:
31530649
3.

A FHIR-Enabled Streaming Sepsis Prediction System for ICUs.

Henry JR, Lynch D, Mals J, Shashikumar SP, Holder A, Sharma A, Nemati S.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:4093-4096. doi: 10.1109/EMBC.2018.8513347.

PMID:
30441256
4.

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.

Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio LC, Van Horn RD, Lin X, Blosser W, Han B, Jin S, Yao S, Bian H, Ficklin C, Fan L, Kapoor A, Antonysamy S, Mc Nulty AM, Froning K, Manglicmot D, Pustilnik A, Weichert K, Wasserman SR, Dowless M, Marugán C, Baquero C, Lallena MJ, Eastman SW, Hui YH, Dieter MZ, Doman T, Chu S, Qian HR, Ye XS, Barda DA, Plowman GD, Reinhard C, Campbell RM, Henry JR, Buchanan SG.

Cancer Discov. 2019 Feb;9(2):248-263. doi: 10.1158/2159-8290.CD-18-0469. Epub 2018 Oct 29.

PMID:
30373917
5.

Transcranial Magnetic Stimulation to the Occipital Place Area Biases Gaze During Scene Viewing.

Malcolm GL, Silson EH, Henry JR, Baker CI.

Front Hum Neurosci. 2018 May 8;12:189. doi: 10.3389/fnhum.2018.00189. eCollection 2018.

6.

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.

Yao YM, Donoho GP, Iversen PW, Zhang Y, Van Horn RD, Forest A, Novosiadly RD, Webster YW, Ebert P, Bray S, Ting JC, Aggarwal A, Henry JR, Tiu RV, Plowman GD, Peng SB.

Clin Cancer Res. 2017 Sep 15;23(18):5547-5560. doi: 10.1158/1078-0432.CCR-16-3250. Epub 2017 Jun 13.

7.

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

Chen SH, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, Mochalkin I, Wong SS, Yue YG, Huber L, Conti I, Henry JR, Starling JJ, Plowman GD, Peng SB.

Cancer Discov. 2016 Mar;6(3):300-15. doi: 10.1158/2159-8290.CD-15-0896. Epub 2016 Jan 5.

8.

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.

Cancer Cell. 2015 Sep 14;28(3):384-98. doi: 10.1016/j.ccell.2015.08.002. Epub 2015 Sep 3.

9.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL.

J Med Chem. 2015 May 28;58(10):4165-79. doi: 10.1021/acs.jmedchem.5b00067. Epub 2015 May 12.

PMID:
25965804
10.

Effects of body size on the oxygen sensitivity of dragonfly flight.

Henry JR, Harrison JF.

J Exp Biol. 2014 Oct 1;217(Pt 19):3447-56. doi: 10.1242/jeb.095828. Epub 2014 Jul 25.

11.

Residential proximity to major highways - United States, 2010.

Boehmer TK, Foster SL, Henry JR, Woghiren-Akinnifesi EL, Yip FY; Centers for Disease Control and Prevention (CDC).

MMWR Suppl. 2013 Nov 22;62(3):46-50.

PMID:
24264489
12.

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.

Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB.

J Biol Chem. 2012 Aug 10;287(33):28087-98. doi: 10.1074/jbc.M112.377218. Epub 2012 Jun 22.

13.

A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.

Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K, Peng SB, McCann DJ.

Mol Cancer Ther. 2011 Nov;10(11):2200-10. doi: 10.1158/1535-7163.MCT-11-0306. Epub 2011 Sep 7.

14.

Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.

Burkholder TP, Clayton JR, Rempala ME, Henry JR, Knobeloch JM, Mendel D, McLean JA, Hao Y, Barda DA, Considine EL, Uhlik MT, Chen Y, Ma L, Bloem LJ, Akunda JK, McCann DJ, Sanchez-Felix M, Clawson DK, Lahn MM, Starling JJ.

Invest New Drugs. 2012 Jun;30(3):936-49. doi: 10.1007/s10637-011-9640-6. Epub 2011 Mar 1. Erratum in: Invest New Drugs. 2012 Jun;30(3):1270-1.

PMID:
21360050
15.

The influence of an elective introductory clinical research course on pharmacy student interest in pursuing research-based careers.

Overholser BR, Foster DR, Henry JR, Plake KS, Sowinski KM.

Am J Pharm Educ. 2010 Nov 10;74(9):165.

16.

Synchrotron imaging of the grasshopper tracheal system: morphological and physiological components of tracheal hypermetry.

Greenlee KJ, Henry JR, Kirkton SD, Westneat MW, Fezzaa K, Lee WK, Harrison JF.

Am J Physiol Regul Integr Comp Physiol. 2009 Nov;297(5):R1343-50. doi: 10.1152/ajpregu.00231.2009. Epub 2009 Aug 26.

17.

Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.

Warshawsky AM, Alt CA, Brozinick JT, Harkness AR, Hawkins ED, Henry JR, Matthews DP, Miller AR, Misener EA, Montrose-Rafizadeh C, Rhodes GA, Shen Q, Vance JA, Udodong UE, Wang M, Zhang TY, Zink RW.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6328-33. Epub 2006 Sep 26.

PMID:
17005394
18.

Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.

Henry JR, Li Y, Warshawsky AM, Brozinick JT, Hawkins ED, Misener EA, Briere DA, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Ajamie RT, Wilken B, Devanarayan V.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6293-7. Epub 2006 Sep 26.

PMID:
17005393
19.

Responses of terrestrial insects to hypoxia or hyperoxia.

Harrison J, Frazier MR, Henry JR, Kaiser A, Klok CJ, Rascón B.

Respir Physiol Neurobiol. 2006 Nov;154(1-2):4-17. Epub 2006 Mar 6. Review.

PMID:
16595193
20.

The development of potent and selective bisarylmaleimide GSK3 inhibitors.

Engler TA, Malhotra S, Burkholder TP, Henry JR, Mendel D, Porter WJ, Furness K, Diefenbacher C, Marquart A, Reel JK, Li Y, Clayton J, Cunningham B, McLean J, O'toole JC, Brozinick J, Hawkins E, Misener E, Briere D, Brier RA, Wagner JR, Campbell RM, Anderson BD, Vaughn R, Bennett DB, Meier TI, Cook JA.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):899-903.

PMID:
15686883
21.
22.

Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.

Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C, Hawkins E, Iversen PW, Li Y, Lindstrom TD, Marquart AL, McLean J, Mendel D, Misener E, Briere D, O'Toole JC, Porter WJ, Queener S, Reel JK, Owens RA, Brier RA, Eessalu TE, Wagner JR, Campbell RM, Vaughn R.

J Med Chem. 2004 Jul 29;47(16):3934-7.

PMID:
15267232
23.

Imidazopyrimidines, potent inhibitors of p38 MAP kinase.

Rupert KC, Henry JR, Dodd JH, Wadsworth SA, Cavender DE, Olini GC, Fahmy B, Siekierka JJ.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.

PMID:
12565927
24.

Investigations on the mechanism of action of the novel antitumor agents 2-benzothiazolyl, 2-benzoxazolyl, and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine.

Hall IH, Peaty NJ, Henry JR, Easmon J, Heinisch G, Pürstinger G.

Arch Pharm (Weinheim). 1999 Apr;332(4):115-23.

PMID:
10327884
25.

Potent inhibitors of the MAP kinase p38.

Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Schafer PH, Siekierka JJ.

Bioorg Med Chem Lett. 1998 Dec 1;8(23):3335-40.

PMID:
9873730
26.

The development of novel and selective p56lck tyrosine kinase inhibitors.

Bullington JL, Cameron JC, Davis JE, Dodd JH, Harris CA, Henry JR, Pellegrino-Gensey JL, Rupert KC, Siekierka JJ.

Bioorg Med Chem Lett. 1998 Sep 22;8(18):2489-94.

PMID:
9873567
27.

6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.

Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Schafer PH, Siekierka JJ.

J Med Chem. 1998 Oct 22;41(22):4196-8. No abstract available.

PMID:
9784093
28.

A hypothesis introducing a new calculation for discal reduction emphasis on stentotic factors and manipulative treatment.

Church CP, Dailey EJ, Henry JR, Goeser CD.

J Manipulative Physiol Ther. 1989 Apr;12(2):151-2. No abstract available.

PMID:
2715739
29.

Tug of war between work and leisure for health care managers.

Henry JR.

Hosp Top. 1983 Jan-Feb;61(1):13-7, 28. No abstract available.

PMID:
10257468
30.

CONGENITAL NEUTROPENIA: A REPORT OF FIVE CASES.

MACGILLIVRAY JB, DACIE JV, HENRY JR, SACKER LS, TIZARD JP.

Acta Paediatr. 1964 Mar;53:188-203. No abstract available.

PMID:
14128179
31.

Congenital Agranulocytosis.

Henry JR.

Proc R Soc Med. 1957 May;50(5):329. No abstract available.

32.

[Uterine inversion by fibroma of uterine fundus].

HENRY JR, SERMENT H.

Bull Fed Soc Gynecol Obstet Lang Fr. 1956 Aug-Sep;8(4):515-6. French. No abstract available.

PMID:
13396410
33.

Subcutaneous emphysema complicating asthma.

HENRY JR.

Arch Dis Child. 1956 Apr;31(156):133-5. No abstract available.

34.

[Anencephalic newborn with cranio-placental adherence].

HENRY JR.

Bull Fed Soc Gynecol Obstet Lang Fr. 1955;7(5):571-2. French. No abstract available.

PMID:
13329494
35.

[Uterine metastasis of an ovarian tumor].

SERMENT H, HENRY JR, PAYAN H, RUF H.

Bull Fed Soc Gynecol Obstet Lang Fr. 1955;7(2):213-5. French. No abstract available.

PMID:
13240277
36.

[Curare in gynecologic and obstetrical surgery].

CASALTA E, HENRY JR, BIMAR J.

Mars Chir. 1950 Sep-Oct;2(4):609-12. Undetermined Language. No abstract available.

PMID:
14805403
37.

Le curare en obstétrique.

CASALTA E, HENRY JR, BIMAR J.

Sud Med Chir. 1949 Dec 31;81(2322):1348-54. Undetermined Language. No abstract available.

PMID:
15403458

Supplemental Content

Loading ...
Support Center